[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 22, 1995

Drug-Resistant Tuberculosis: Inconsistent Results of Pyrazinamide Susceptibility Testing

Author Affiliations

Lincoln Medical and Mental Health Center Bronx, NY

JAMA. 1995;273(12):916-917. doi:10.1001/jama.1995.03520360030022
Abstract

To the Editor.  —Pyrazinamide, in combination with isoniazid and rifampin, often plays a prominent role in the therapy of tuberculosis.1 Frequently, pyrazinamide susceptibility testing is performed, and the results generally dictate if pyrazinamide will or will not be used as a component of treatment of or prophylaxis for drug-resistant tuberculosis. Recently, our institution had a nosocomial outbreak of drug-resistant tuberculosis. When identically paired isolates were sent to two reference laboratories, however, discordant pyrazinamide susceptibility results were reported.From 1991 to 1993, a total of 55 patients with tuberculosis resistant to rifampin, isoniazid, streptomycin sulfate, and ethambutol hydrochloride were identified by our institution.2 Ten identically paired isolates of Mycobacterium tuberculosis from 10 different patients were sent to two reference laboratories for susceptibility testing. Restriction fragment length polymorphism (RFLP) analyses were performed by the Centers for Disease Control and Prevention (CDC), the Public Health Research Institute, and/or the Albert Einstein

First Page Preview View Large
First page PDF preview
First page PDF preview
×